If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A Spanish research group of the public health system has developed a new composition to prevent, alleviate, ameliorate and treat diseases or disorders related to Parkinson's disease.
A license agreement or an technical cooperation agreement for a public or private partnership for the further development of the patented composition is sought.
Neurodegenerative disease is an umbrella term for a range of conditions which primarily affect the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Neurons normally do not reproduce or replace themselves, so when they become damaged or die they cannot be replaced by the body. Examples of neurodegenerative diseases include Parkinson's, Alzheimer's, and Huntington's disease.
A Spanish hospital research group has developed a new composition to prevent, alleviate, ameliorate and treat diseases or disorders specially related to Parkinson's disease. The composition takes into account the relevant role of the enteric nervous system in the pathogenesis of Parkinson's disease (PD) and the connection between inflammatory intestinal diseases and bacterial flora. This connection supposes a new composition that consists of at least one aminosalicylate as active ingredient.
The use of the composition is preventive: the administration is carried out before the diagnosis of the disease, or in the first stages.
The research group is looking for the following collaboration:
-License agreement: framework of authorizing the interested parties to use the technology.
-Technical cooperation agreement: to collaborate with other research teams, companies or foundations.
- The connection between inflammatory intestinal diseases and bacterial flora suppose a new composition that can be used to prevent, alleviate, ameliorate and treat Parkinson's disease.
- The composition acts as a protective factor by preventing the spread of alfa synuclein in the intestine as a result of a
modification in the bacterial flora when the patient is
suffering an intestinal inflammation.
- It is possible to use this composition with others drugs as a
PCT patent application
The research group aims to formalize a technology transfer process through a license agreement. The potential partner can be public or private entities interested in the implementation of the solution. The company is already selling the technology in Spain and now they are open to establish agreements with both European and non-European companies.
If there are some entities, such as R&D centres, technology centres or specialized companies, interested in collaborating and developing further aspects of the solution, a technical cooperation agreement could be envisaged. They can also be European or non-European entities.